New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
05:32 EDTBAX, CTICCTI BioPharma completes recruitment in PERSIST-1 Pacritinib Phase 3 trial
CTI BioPharma (CTIC) announced that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis. Under the development and commercialization agreement for pacritinib with Baxter International (BAX), CTI expects to receive a $20M development milestone payment in connection with the first treatment dosing of the last patient enrolled in PERSIST-1. CTI expects to achieve this milestone and receive payment by mid-Q3.
News For CTIC;BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
17:29 EDTBAXBaxalta files to sell $1.45B of common stock for holders
Subscribe for More Information
August 27, 2015
10:06 EDTBAXHigh option volume stocks
High option volume stocks: GLOG ACI NGD BEAT BAX TTPH STJ FNF SSTK
August 21, 2015
10:29 EDTCTICCTI BioPharma strength attributed to abstract posted on PubMed
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use